Accelerating First-in-Class Antibody Discovery with High-Fidelity Biological Datasets.

The Challenge

The firm's core objective was to build advanced Machine Learning models for antibody discovery. However, they faced a critical bottleneck: ingesting and structuring highly complex biological data.

Existing datasets failed to meet the dual requirements of rigorous scientific research and AI model training. Furthermore, reconciling data across cross-functional teams (scientists, data engineers, and legal) was slowing down target identification and introducing IP compliance risks.

The Solution

Eureka deployed a 'Standardized Data Flatfile' delivery model tailored for AI drug discovery. We provided a comprehensive, highly-indexed antibody sequence database covering global public antibody information.

This included deeply validated antibody-antigen (AB-AG) pairs, standardized epitope sequences directly mapped to antigens, and comprehensive affinity metrics (IC50, EC50). The data was pre-cleaned and standardized, ready for immediate ingestion into their ML pipelines.

The Impact

• Enhanced Model Performance: The deeply validated and indexed datasets significantly improved the accuracy and operational performance of their antibody discovery ML models.
• Accelerated R&D: Dramatically shortened the antibody drug R&D cycle and reduced trial-and-error costs, accelerating the path to market for first-in-class drugs.
• Compliance & IP Security: Simplified complex data ingestion while providing strict compliance documentation, eliminating intellectual property risks for AI-generated insights.